Unlearn.AI has raised $15M in funding from Radical Ventures and Wittington Ventures to expand partnerships and accelerate regulatory approval, valuing the startup at $265M.
The biotech startup has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, which could potentially revolutionize healthcare, diagnostics, and treatment.
Unlearn.AI's platform uses generative AI to build digital twins to speed up clinical drug trials.
- This could reduce the enrollments needed for clinical trials by replacing patients who receive a placebo.
- Unlearn.AI focuses on a novel application of generative AI.
- AI learns how to take actions from past data.
- Its technology is critical to commercializing the platform to global drugmakers.
- Unlearn.AI has raised $85M from investors including Insight Partners, 8VC, and Mubadala Ventures.
In September 2022, the company won approval from the European Medicines Agency to use its AI-driven approach.
